CSL Annual Report 2022

CSL Limited Annual Report 2021/22 57 Carolyn Hewson AO BEc (Hons), MA Independent Non-Executive Director Director of CSL Limited since December 2019. Ms Hewson is a former investment banker with over 35 years’ experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long-termNon-Executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer of the Order of Australia for her services to the broader community and to business. Other directorships and offices (current and recent): – Director of Reserve Bank of Australia (since April 2021); – Director of Infrastructure SA (since January 2019); – Former Member of Federal Government Growth Centres Advisory Committee (from January 2015 to May 2021); – Former Director of BHP Group Limited and BHP Group Plc (fromMarch 2010 to November 2019); and – Former Trustee Westpac Foundation (fromMay 2015 to May 2019). Board Committee memberships: – Chair of the Corporate Governance and Nomination Committee; – Member of the Audit and Risk Management Committee; and – Member of the Human Resources and Remuneration Committee. Duncan Maskell MA, PhD, FMedSci, Hon Assoc RSVC Independent Non-Executive Director Director of CSL Limited since August 2021. Professor Maskell has wide-ranging international experience in science and commerce, with a particular focus in research, academia and entrepreneurship. Professor Maskell is the vice-chancellor of the University of Melbourne. Prior to this he was senior pro-vice-chancellor at the University of Cambridge in the UK and has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Professor Maskell has extensive experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-Executive Director of Genus Plc, a FTSE 250 company. Professor Maskell holds a Master of Arts and a Doctor of Philosophy from the University of Cambridge. Other directorships and offices (current and recent): – Director of the Grattan Institute (since November 2018); – Vice-Chancellor of the University of Melbourne (since October 2018); – Director of Melbourne Business School (since October 2018); – Director of the Group of Eight Limited (since October 2018); and – Director of Universities Australia Limited (since October 2018). Board Committee membership: – Member of the Innovation and Development Committee. Marie McDonald BSc (Hons), LLB (Hons) Independent Non-Executive Director Director of CSL Limited since August 2013. Ms McDonald has significant executive and Non-Executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years’ experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a member of the Australian Takeovers Panel for nine years. Other directorships and offices (current and recent): – Member of Melbourne University Law School Foundation Board (since October 2021); – Director of Nanosonics Limited (since October 2016); – Director of Nufarm Limited (since March 2017); and – Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). Board Committee memberships: – Member of the Audit and Risk Management Committee; and – Member of the Human Resources and Remuneration Committee.

RkJQdWJsaXNoZXIy MjE2NDg3